within Pharmacolibrary.Drugs.ATC.J;

model J05AP07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.67,
    Cl             = 0.0002483333333333333,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.047,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01933333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.101,
    k12             = 8.32,
    k21             = 8.32
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AP07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Daclatasvir is a direct-acting antiviral medication that acts as an inhibitor of the HCV NS5A protein, thereby inhibiting hepatitis C virus (HCV) replication. It is approved for use, often in combination with other antivirals, for the treatment of chronic HCV infection in adults.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in healthy adult subjects (sex not specified) after single oral dose.</p><h4>References</h4><ol><li><p>Elbadawy, HA, et al., &amp; El-Demerdash, E (2022). Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450. <i>Current drug metabolism</i> 23(6) 484–495. DOI:<a href=&quot;https://doi.org/10.2174/1389200223666220404134524&quot;>10.2174/1389200223666220404134524</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35379125/&quot;>https://pubmed.ncbi.nlm.nih.gov/35379125</a></p></li><li><p>Gandhi, Y, et al., &amp; Garimella, T (2018). Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. <i>Clinical pharmacokinetics</i> 57(8) 911–928. DOI:<a href=&quot;https://doi.org/10.1007/s40262-017-0624-3&quot;>10.1007/s40262-017-0624-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29353349/&quot;>https://pubmed.ncbi.nlm.nih.gov/29353349</a></p></li><li><p>Dogra, A, et al., &amp; Nandi, U (2018). Intervention of curcumin on oral pharmacokinetics of daclatasvir in rat: A possible risk for long-term use. <i>Phytotherapy research : PTR</i> 32(10) 1967–1974. DOI:<a href=&quot;https://doi.org/10.1002/ptr.6123&quot;>10.1002/ptr.6123</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29806225/&quot;>https://pubmed.ncbi.nlm.nih.gov/29806225</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AP07;
